Han, Guangzhou

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 336

3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry

Cancer, Hypoxia, and MetabolismHeterocyclic Compound Synthesis and Bioactivity

Cited by 220

Mutation of the androgen receptor causes oncogenic transformation of the prostate.

Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., DeMayo, F. J., Tilley, W., & Greenberg, N. M. (2005) · Proceedings of the National Academy of Sciences

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 192